

Richard S Finn

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7945925/publications.pdf>

Version: 2024-02-01

81
papers

13,889
citations

136740

32
h-index

76769

74
g-index

83
all docs

83
docs citations

83
times ranked

12914
citing authors

#	ARTICLE	IF	CITATIONS
1	Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2017, 389, 56-66.	6.3	2,771
2	Palbociclib and Letrozole in Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 1925-1936.	13.9	1,943
3	Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. <i>Lancet Oncology, The</i> , 2018, 19, 940-952.	5.1	1,816
4	Molecular therapies and precision medicine for hepatocellular carcinoma. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 599-616.	12.5	1,308
5	Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased Î±-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2019, 20, 282-296.	5.1	1,202
6	Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 2960-2970.	0.8	723
7	Immunotherapies for hepatocellular carcinoma. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 151-172.	12.5	643
8	Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. <i>Lancet Oncology, The</i> , 2022, 23, 77-90.	5.1	526
9	Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. <i>Oncogene</i> , 1998, 17, 2235-2249.	2.6	353
10	Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial. <i>Journal of Hepatology</i> , 2018, 69, 353-358.	1.8	270
11	Biomarkers Associated With Response to Regorafenib in Patients With Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2019, 156, 1731-1741.	0.6	160
12	Purification of HCC-specific extracellular vesicles on nanosubstrates for early HCC detection by digital scoring. <i>Nature Communications</i> , 2020, 11, 4489.	5.8	134
13	Biologic effects of heregulin/neu differentiation factor on normal and malignant human breast and ovarian epithelial cells. <i>Oncogene</i> , 1999, 18, 6050-6062.	2.6	131
14	Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond. <i>Cancer Treatment Reviews</i> , 2018, 68, 16-24.	3.4	124
15	Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women with Treatment-Naïve Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 110-121.	3.2	120
16	Overall survival (OS) with first-line palbociclib plus letrozole (PAL+LET) versus placebo plus letrozole (PBO+LET) in women with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer (ER+/HER2~ ABC): Analyses from PALOMA-2.. <i>Journal of Clinical Oncology</i> , 2022, 40, LBA1003-LBA1003.	0.8	95
17	Lenvatinib (len) plus pembrolizumab (pembro) for the first-line treatment of patients (pts) with advanced hepatocellular carcinoma (HCC): Phase 3 LEAP-002 study.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS4152-TPS4152.	0.8	94
18	Radiofrequency ablation of hepatocellular carcinoma as bridge therapy to liver transplantation: A 10-year intention-to-treat analysis. <i>Hepatology</i> , 2017, 65, 1979-1990.	3.6	87

#	ARTICLE	IF	CITATIONS
19	Bilateral Subfoveal Neurosensory Retinal Detachment Associated With MEK Inhibitor Use for Metastatic Cancer. <i>JAMA Ophthalmology</i> , 2014, 132, 1005.	1.4	74
20	A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor. <i>British Journal of Cancer</i> , 2017, 116, 575-583.	2.9	73
21	Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2~ advanced breast cancer (PALOMA-1, TRIO-18). <i>Breast Cancer Research and Treatment</i> , 2020, 183, 419-428.	1.1	73
22	PALOMA-2: Primary results from a phase III trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmenopausal women with ER+/HER2~ advanced breast cancer (ABC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 507-507.	0.8	72
23	Evolution of Systemic Therapy for Hepatocellular Carcinoma. <i>Hepatology</i> , 2021, 73, 150-157.	3.6	70
24	Current and Future Treatment Strategies for Patients with Advanced Hepatocellular Carcinoma: Role of mTOR Inhibition. <i>Liver Cancer</i> , 2012, 1, 247-256.	4.2	65
25	Palbociclib plus endocrine therapy in older women with HR+/HER2~ advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies. <i>European Journal of Cancer</i> , 2018, 101, 123-133.	1.3	59
26	A novel multimarker assay for the phenotypic profiling of circulating tumor cells in hepatocellular carcinoma. <i>Liver Transplantation</i> , 2018, 24, 946-960.	1.3	58
27	Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2-Advanced Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2019, 111, 419-430.	3.0	55
28	A phase Ib study of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 4519-4519.	0.8	50
29	Palbociclib with Letrozole in Postmenopausal Women with ER+/HER2~ Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA-2 Trial. <i>Oncologist</i> , 2019, 24, 1514-1525.	1.9	49
30	Stereotactic body radiotherapy (SBRT) for locally advanced extrahepatic and intrahepatic cholangiocarcinoma. <i>Advances in Radiation Oncology</i> , 2016, 1, 237-243.	0.6	43
31	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma. , 2021, 9, e002794.		43
32	Ramucirumab in advanced hepatocellular carcinoma in REACH-2: the true value of α -fetoprotein. <i>Lancet Oncology</i> , The, 2019, 20, e191.	5.1	42
33	Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab. <i>British Journal of Cancer</i> , 2021, 124, 1388-1397.	2.9	39
34	IMbrave150: A randomized phase III study of 1L atezolizumab plus bevacizumab vs sorafenib in locally advanced or metastatic hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS4141-TPS4141.	0.8	38
35	Randomized Phase 3 LEAP-012 Study: Transarterial Chemoembolization With or Without Lenvatinib Plus Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma Not Amenable to Curative Treatment. <i>CardioVascular and Interventional Radiology</i> , 2022, 45, 405-412.	0.9	35
36	Palbociclib Plus Letrozole as First-Line Therapy in Postmenopausal Asian Women With Metastatic Breast Cancer: Results From the Phase III, Randomized PALOMA-2 Study. <i>Journal of Global Oncology</i> , 2019, 5, 1-19.	0.5	34

#	ARTICLE	IF	CITATIONS
37	Characterization of Neutropenia in Advanced Cancer Patients Following Palbociclib Treatment Using a Population Pharmacokinetic-Pharmacodynamic Modeling and Simulation Approach. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 1159-1173.	1.0	30
38	Persisting risk of hepatocellular carcinoma after hepatitis C virus cure monitored by a liver transcriptome signature. <i>Hepatology</i> , 2017, 66, 1344-1346.	3.6	28
39	Determination of hepatocellular carcinoma grade by needle biopsy is unreliable for liver transplant candidate selection. <i>Liver Transplantation</i> , 2017, 23, 1123-1132.	1.3	27
40	A phase I study of MEK inhibitor MEK162 (ARRY-438162) in patients with biliary tract cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, 220-220.	0.8	27
41	Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma. <i>British Journal of Cancer</i> , 2019, 121, 218-221.	2.9	22
42	Progression-free Survival Outcome Is Independent of Objective Response in Patients With Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer Treated With Palbociclib Plus Letrozole Compared With Letrozole: Analysis From PALOMA-2. <i>Clinical Breast Cancer</i> , 2020, 20, e173-e180.	1.1	21
43	Treatment effect of palbociclib plus endocrine therapy by prognostic and intrinsic subtype and biomarker analysis in patients with bone-only disease: a joint analysis of PALOMA-2 and PALOMA-3 clinical trials. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 23-35.	1.1	21
44	Impact of Dose Reduction on Efficacy: Implications of Exposure-Response Analysis of Palbociclib. <i>Targeted Oncology</i> , 2021, 16, 69-76.	1.7	19
45	DEPTOR is linked to a TORC1-p21 survival proliferation pathway in multiple myeloma cells. <i>Genes and Cancer</i> , 2014, 5, 407-419.	0.6	19
46	Molecular markers of response to anti-PD1 therapy in advanced hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 4100-4100.	0.8	17
47	Somatic copy number profiling from hepatocellular carcinoma circulating tumor cells. <i>Npj Precision Oncology</i> , 2020, 4, 16.	2.3	16
48	Outcomes with sorafenib (SOR) followed by regorafenib (REG) or placebo (PBO) for hepatocellular carcinoma (HCC): Results of the international, randomized phase 3 RESORCE trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, 344-344.	0.8	16
49	Evaluation of the Association of Polymorphisms With Palbociclib-Induced Neutropenia: Pharmacogenetic Analysis of PALOMA-2/-3. <i>Oncologist</i> , 2021, 26, e1143-e1155.	1.9	15
50	Lapatinib, a Dual-Targeted Small Molecule Inhibitor of EGFR and HER2, in HER2-Amplified Breast Cancer: From Bench to Bedside. <i>Clinical Medicine Insights Therapeutics</i> , 2011, 3, CMT.S3783.	0.4	13
51	Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab. <i>Liver International</i> , 2021, 41, 598-607.	1.9	13
52	Saudi Association for the Study of Liver diseases and Transplantation practice guidelines on the diagnosis and management of hepatocellular carcinoma. <i>Saudi Journal of Gastroenterology</i> , 2020, 26, 1.	0.5	13
53	Pembrolizumab (pembro) vs placebo (pbo) in patients (pts) with advanced hepatocellular carcinoma (aHCC) previously treated with sorafenib: Updated data from the randomized, phase III KEYNOTE-240 study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 268-268.	0.8	10
54	Efficacy and safety of palbociclib plus endocrine therapy in North American women with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. <i>Breast Journal</i> , 2020, 26, 368-375.	0.4	8

#	ARTICLE	IF	CITATIONS
55	A randomized, multicenter, double-blind phase III study of palbociclib (PD-0332991), an oral CDK 4/6 inhibitor, plus letrozole versus placebo plus letrozole for the treatment of postmenopausal women with ER(+), HER2(â€“) breast cancer who have not received any prior systemic anticancer treatment for advanced disease.. <i>Journal of Clinical Oncology</i> , 2013, 31, TPS652-TPS652.	0.8	7
56	Neratinib to inhibit the growth of triple-negative breast cancer cells.. <i>Journal of Clinical Oncology</i> , 2015, 33, 1099-1099.	0.8	7
57	Metiv-HCC: A phase III clinical trial evaluating tivantinib (ARQ 197), a MET inhibitor, versus placebo as second-line in patients (pts) with MET-high inoperable hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2013, 31, TPS4159-TPS4159.	0.8	6
58	Clinical efficacy and safety profile of palbociclib (P) in combination with letrozole (L) as first-line treatment in patients (pts) with ER+ and HER2- advanced breast cancer (ABC) who have not received any systemic treatment (ST): A subgroup analysis of PALOMA-1/TRIO-18.. <i>Journal of Clinical Oncology</i> , 2015, 33, 575-575.	0.8	6
59	Regorafenib in patients with unresectable hepatocellular carcinoma (uHCC) in routine clinical practice: Exploratory analysis of overall survival (OS) in the prospective, observational REFINE study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 433-433.	0.8	6
60	Ramucirumab in patients with advanced hepatocellular carcinoma and elevated Î± â€“fetoprotein: Outcomes by treatmentâ€“emergent ascites. <i>Hepatology Research</i> , 2021, 51, 715-721.	1.8	5
61	Phase I study of H3B-6527 in hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma (ICC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 4090-4090.	0.8	5
62	Ramucirumab for Patients with Intermediate-Stage Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Results from Two Phase 3 Studies (REACH and REACH-2). <i>Liver Cancer</i> , 2021, 10, 451-460.	4.2	5
63	Continuous-dose regorafenib (REG) in hepatocellular carcinoma (HCC): Phase I safety and pharmacokinetic (PK) study.. <i>Journal of Clinical Oncology</i> , 2013, 31, 300-300.	0.8	5
64	Long-term safety profile of palbociclib (P) in combination with letrozole (L) as first-line treatment for postmenopausal patients with ER+ and HER2- advanced breast cancer (ABC) (PALOMA-1/TRIO-18).. <i>Journal of Clinical Oncology</i> , 2015, 33, 570-570.	0.8	5
65	Sequential treatment with sorafenib (SOR) followed by regorafenib (REG) in patients (pts) with unresectable hepatocellular carcinoma (HCC): Interim analysis of the observational REFINE study.. <i>Journal of Clinical Oncology</i> , 2020, 38, e16680-e16680.	0.8	5
66	Regorafenib in patients with unresectable hepatocellular carcinoma (uHCC) in routine clinical practice: Interim analysis of the prospective, observational REFINE trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, 542-542.	0.8	4
67	Ramucirumab for patients with advanced hepatocellular carcinoma and elevated Î± â€“fetoprotein following a non-sorafenib based first-line therapy: Final results from an expansion cohort of REACH-2.. <i>Journal of Clinical Oncology</i> , 2022, 40, 423-423.	0.8	3
68	Pembrolizumab (pembro) versus placebo (pbo) in patients (pts) with advanced hepatocellular carcinoma (aHCC) previously treated with sorafenib: Updated data from the randomized, phase 3 KEYNOTE-240 study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 4072-4072.	0.8	2
69	Efficacy and safety of first-line palbociclib plus letrozole compared with letrozole alone in patients aged â‰¥ 65 years with estrogen receptor-positive, HER2-negative advanced breast cancer: A subgroup analysis by age of the PALOMA-1/TRIO-18 trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, 571-571.	0.8	2
70	Effect of pembrolizumab (pembro) on hepatitis B viral (HBV) load and aminotransferase (ALT) levels in patients (pts) with advanced hepatocellular carcinoma (aHCC) in KEYNOTE-224 and KEYNOTE-240.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4587-4587.	0.8	2
71	LEAP-012 trial in progress: Transarterial chemoembolization (TACE) with or without lenvatinib plus pembrolizumab for intermediate-stage hepatocellular carcinoma (HCC). <i>Journal of Clinical Oncology</i> , 2022, 40, TPS494-TPS494.	0.8	2
72	Exploratory circulating biomarker analyses: lenvatinib + pembrolizumab (L + P) in a phase 1b trial in unresectable hepatocellular carcinoma (uHCC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 4084-4084.	0.8	1

#	ARTICLE	IF	CITATIONS
73	The effect of palbociclib (P) in combination with letrozole (L) on bone metastases in women with ER+/HER2- metastatic breast cancer (MBC): Subanalysis from a randomized phase II study.. Journal of Clinical Oncology, 2015, 33, 572-572.	0.8	1
74	Regorafenib (REG) in patients with hepatocellular carcinoma (HCC) progressing following sorafenib: An ongoing randomized, double-blind, phase III trial.. Journal of Clinical Oncology, 2013, 31, TPS4163-TPS4163.	0.8	1
75	<i>Hepatic Oncology</i>: a journal for all stakeholders in liver cancer management. Hepatic Oncology, 2014, 1, 1-1.	4.2	0
76	Landmark analysis of overall survival (OS) by objective response (OR) in previously treated patients (pts) with advanced hepatocellular carcinoma (aHCC): Post-hoc analysis of the randomized, phase III KEYNOTE-240 study.. Journal of Clinical Oncology, 2021, 39, 318-318.	0.8	0
77	Landmark analysis of overall survival (OS) by objective response (OR) in previously treated patients (pts) with advanced hepatocellular carcinoma (aHCC): Post hoc analysis of the randomized, phase 3 KEYNOTE-240 study.. Journal of Clinical Oncology, 2021, 39, e16122-e16122.	0.8	0
78	Prognostic and predictive factors in patients treated with ramucirumab (RAM) with advanced hepatocellular carcinoma (aHCC) and elevated alpha-fetoprotein (AFP): Results from two phase III trials.. Journal of Clinical Oncology, 2021, 39, 4146-4146.	0.8	0
79	Phase I trial of sorafenib in high-risk hepatocellular carcinoma (HCC) patients after liver transplantation.. Journal of Clinical Oncology, 2013, 31, 280-280.	0.8	0
80	Multicenter phase I trial of sorafenib (S) in high-risk hepatocellular carcinoma (HCC) patients after liver transplantation (LT).. Journal of Clinical Oncology, 2014, 32, 285-285.	0.8	0
81	Abstract PD2-07: Impact of using cross-platform gene expression profiling technologies and computational methods for intrinsic breast cancer subtyping in PALOMA-2 and PALLET. Cancer Research, 2022, 82, PD2-07-PD2-07.	0.4	0